ClinicalTrials.gg
CompletedNCT02872714Updated Aug 14, 2025Results posted

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

A Phase 2 interventional study of pemigatinib and pemigatinib in UC (Urothelial Cancer), sponsored by Incyte Corporation. Completed at 96 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
263
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Carcinoma, Transitional Cell by Incyte Corporation — none open to participants now, none under way, none of them phase 3. Carcinoma, Transitional Cell · Incyte Corporation.

Enrollment
Largest of 12
263 · median 46
Started
2017
with 4 others
Phase 2
3 of 12
none open now
Registered
1st of 12
by date

Among the 12 studies in Carcinoma, Transitional Cell by Incyte Corporation, this one has the largest enrollment, is one of 5 that started in 2017, is one of 3 in phase 2, and was the 1st registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

None of the 12 studies in Carcinoma, Transitional Cell by Incyte Corporation is open now. The open studies under Carcinoma, Transitional Cell, anywhere →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Carcinoma, Transitional Cell by Incyte Corporation as a file.
02

Study summary

The purpose of this study is to evaluate the overall response rate (ORR) of pemigatinib as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.

03

Conditions studied

  • UC (Urothelial Cancer)

Keywords

  • Urothelial carcinoma
  • fibroblast growth factor (FGF)
  • fibroblast growth factor receptor (FGFR)
  • FGF/FGFR alterations
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 20 years and older in Japan
  • documented or surgically unresectable urothelial carcinoma; may include primary site from urethra, ureters, upper tract, renal pelvis, and bladder.
  • (ECOG) performance status of 0-2.
  • ≥ 12 weeks.
  • Radiographically measurable per v1.1.
  • Documented FGF/FGFR alteration and have either 1a) failed at least 1 previous treatment for their metastatic or surgically unresectable urothelial carcinoma (ie, chemotherapy, immunotherapy) or 1b) have not received chemotherapy due to poor ECOG status or 2) have insufficient renal function.

Exclusion criteria

Exclusion Criteria:

  • Prior receipt of a selective FGFR inhibitor.
  • Use of any potent inhibitors or inducers within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug.
  • Inability or unwillingness to swallow pemigatinib or significant gastrointestinal disorder(s) that could interfere with the absorption, metabolism, or excretion of pemigatinib.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
263 participants (actual)

Study arms

  • Experimental
    Cohort A-ID (Intermittent Dose) Pemigatinib

    Pemigatinib in subjects with FGFR3 mutations or fusions.

    Drug: pemigatinib

  • Experimental
    Cohort A-CD (Continuous Dose) Pemigatinib

    Pemigatinib in subjects with FGFR3 mutations or fusions.

    Drug: pemigatinib

  • Experimental
    Cohort B Pemigatinib

    Pemigatinib in subjects with other FGF/FGFR alterations.

    Drug: pemigatinib

Interventions

  • Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.

    Also known as: INCB054828

  • Pemigatinib once a day by mouth continuously.

    Also known as: INCB054828

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) in Participants With FGFR3 Mutations or Fusions on a CD Regimen

    ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) at any post-Baseline visit prior to first progressive disease (PD), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1). CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed.

    Time frame: up to 1138 days

Secondary outcomes

  1. ORR in Participants With FGFR3 Mutations or Fusions on an ID Regimen

    ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed.

    Time frame: up to 817 days

  2. ORR in Participants With All Other FGF/FGFR Alterations

    ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed.

    Time frame: up to 1198 days

  3. ORR in All Participants on an ID or CD Regimen in Combined Cohorts

    ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed.

    Time frame: up to 1198 days

  4. Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. Abnormal laboratory values or test results occurring after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). A TEAE was any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug and within 30 days of the last dose of study drug.

    Time frame: up to approximately 25 weeks

  5. Progression-free Survival (PFS)

    PFS was defined as the length of time from the start of the study drug (Day 1) to the earlier of death or disease progression by RECIST v1.1, as assessed by the independent centralized radiological review committee.

    Time frame: up to 1138 days

  6. Duration of Response (DOR)

    DOR was defined as the time from the first overall response contributing to an objective response (CR or PR) to the earlier of death or first overall response of PD occurring after the first overall response contributing to the objective response. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed

    Time frame: up to 1075 days

  7. Overall Survival

    Overall survival was defined as the length of time from the start of the study drug (Day 1) until the date of death due to any cause.

    Time frame: up to 1610 days

07

Results

Posted Mar 24, 2023

Participant flow

Participant flow — Overall Study
MilestoneCohort A-ID: FGFR3 Mutations or FusionsCohort B-ID: All Other FGF/FGFR AlterationsOther-IDCohort A-CD: FGFR3 Mutations or FusionsOther-CD
Started1034491013
Completed1021131
Not completed93428882
Withdrew: Progressive disease12000
Withdrew: Death87368812
Withdrew: Lost to follow-up21030
Withdrew: Physician decision00010
Withdrew: Withdrawal by subject13020
Withdrew: Captured as other20010

Outcome measures

PrimaryObjective Response Rate (ORR) in Participants With FGFR3 Mutations or Fusions on a CD Regimen

ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) at any post-Baseline visit prior to first progressive disease (PD), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1). CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed.

Time frame:
up to 1138 days
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) in Participants With FGFR3 Mutations or Fusions on a CD Regimen
percentage of participantsCohort A-ID: FGFR3 Mutations or FusionsCohort B-ID: All Other FGF/FGFR AlterationsOther-IDCohort A-CD: FGFR3 Mutations or FusionsOther-CD
Objective Response Rate (ORR) in Participants With FGFR3 Mutations or Fusions on a CD Regimen———17.8 (10.92 to 26.70)—
SecondaryORR in Participants With FGFR3 Mutations or Fusions on an ID Regimen

ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed.

Time frame:
up to 817 days
Reported as:
Number · percentage of participants
ORR in Participants With FGFR3 Mutations or Fusions on an ID Regimen
percentage of participantsCohort A-ID: FGFR3 Mutations or FusionsCohort B-ID: All Other FGF/FGFR AlterationsOther-IDCohort A-CD: FGFR3 Mutations or FusionsOther-CD
ORR in Participants With FGFR3 Mutations or Fusions on an ID Regimen23.3 (15.54 to 32.66)————
SecondaryORR in Participants With All Other FGF/FGFR Alterations

ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed.

Time frame:
up to 1198 days
Reported as:
Number · percentage of participants
ORR in Participants With All Other FGF/FGFR Alterations
percentage of participantsCohort A-ID: FGFR3 Mutations or FusionsCohort B-ID: All Other FGF/FGFR AlterationsOther-IDCohort A-CD: FGFR3 Mutations or FusionsOther-CD
ORR in Participants With All Other FGF/FGFR Alterations—6.8 (1.43 to 18.66)———
SecondaryORR in All Participants on an ID or CD Regimen in Combined Cohorts

ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed.

Time frame:
up to 1198 days
Reported as:
Number · percentage of participants
ORR in All Participants on an ID or CD Regimen in Combined Cohorts
percentage of participantsCohort A-ID: FGFR3 Mutations or FusionsCohort B-ID: All Other FGF/FGFR AlterationsOther-IDCohort A-CD: FGFR3 Mutations or FusionsOther-CDCohort A-ID + Cohort B-IDCohort A-ID + Cohort A-CDCohort A-ID + Cohort B-ID + Cohort A-CD
ORR in All Participants on an ID or CD Regimen in Combined Cohorts—————18.4 (12.47 to 25.59)20.6 (15.26 to 26.79)18.1 (13.55 to 23.52)
SecondaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE)

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. Abnormal laboratory values or test results occurring after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). A TEAE was any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug and within 30 days of the last dose of study drug.

Time frame:
up to approximately 25 weeks
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsCohort A-ID: FGFR3 Mutations or FusionsCohort B-ID: All Other FGF/FGFR AlterationsOther-IDCohort A-CD: FGFR3 Mutations or FusionsOther-CD
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)1034491003
SecondaryProgression-free Survival (PFS)

PFS was defined as the length of time from the start of the study drug (Day 1) to the earlier of death or disease progression by RECIST v1.1, as assessed by the independent centralized radiological review committee.

Time frame:
up to 1138 days
Reported as:
Median · months
Progression-free Survival (PFS)
monthsCohort A-ID: FGFR3 Mutations or FusionsCohort B-ID: All Other FGF/FGFR AlterationsOther-IDCohort A-CD: FGFR3 Mutations or FusionsOther-CD
Progression-free Survival (PFS)4.27 (3.91 to 6.05)2.04 (1.87 to 2.17)—4.04 (3.45 to 4.17)—
SecondaryDuration of Response (DOR)

DOR was defined as the time from the first overall response contributing to an objective response (CR or PR) to the earlier of death or first overall response of PD occurring after the first overall response contributing to the objective response. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed

Time frame:
up to 1075 days
Reported as:
Median · months
Duration of Response (DOR)
monthsCohort A-ID: FGFR3 Mutations or FusionsCohort B-ID: All Other FGF/FGFR AlterationsOther-IDCohort A-CD: FGFR3 Mutations or FusionsOther-CD
Duration of Response (DOR)6.21 (4.60 to 7.95)10.02 (8.38 to NA)—6.23 (4.14 to 8.25)—
SecondaryOverall Survival

Overall survival was defined as the length of time from the start of the study drug (Day 1) until the date of death due to any cause.

Time frame:
up to 1610 days
Reported as:
Median · months
Overall Survival
monthsCohort A-ID: FGFR3 Mutations or FusionsCohort B-ID: All Other FGF/FGFR AlterationsOther-IDCohort A-CD: FGFR3 Mutations or FusionsOther-CD
Overall Survival8.90 (7.46 to 15.18)9.13 (5.52 to 17.05)—6.80 (5.26 to 9.10)—

Adverse events

Collected over Adverse events were assessed for up to approximately 25 weeks; All-cause Mortality was assessed for up to 1610 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A-ID: FGFR3 Mutations or Fusions88/103 (85.4%)45/103 (43.7%)101/103 (98.1%)
Cohort B-ID: All Other FGF/FGFR Alterations39/44 (88.6%)26/44 (59.1%)43/44 (97.7%)
Other-ID8/9 (88.9%)3/9 (33.3%)9/9 (100%)
Cohort A-CD: FGFR3 Mutations or Fusions83/101 (82.2%)48/101 (47.5%)99/101 (98%)
Other-CD2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Most frequent serious events
Showing 10 of 139
Most frequent serious events
EventCohort A-ID: FGFR3 Mutations or FusionsCohort B-ID: All Other FGF/FGFR AlterationsOther-IDCohort A-CD: FGFR3 Mutations or FusionsOther-CD
AnaemiaBlood and lymphatic system disorders0/1031/440/92/1011/3
Back painMusculoskeletal and connective tissue disorders2/1032/440/91/1011/3
HyponatraemiaMetabolism and nutrition disorders0/1032/440/91/1011/3
CoughRespiratory, thoracic and mediastinal disorders0/1030/441/90/1010/3
HaematuriaRenal and urinary disorders4/1031/441/90/1010/3
PyrexiaGeneral disorders1/1031/441/91/1010/3
Spinal cord infectionInfections and infestations0/1030/441/90/1010/3
Acute kidney injuryRenal and urinary disorders3/1034/440/92/1010/3
Urinary tract infectionInfections and infestations6/1031/440/98/1010/3
ConstipationGastrointestinal disorders2/1033/440/90/1010/3
Most frequent other events
Showing 10 of 137
Most frequent other events
EventCohort A-ID: FGFR3 Mutations or FusionsCohort B-ID: All Other FGF/FGFR AlterationsOther-IDCohort A-CD: FGFR3 Mutations or FusionsOther-CD
AlopeciaSkin and subcutaneous tissue disorders49/10316/447/938/1011/3
Dry mouthGastrointestinal disorders33/10313/447/939/1011/3
Abdominal painGastrointestinal disorders20/10311/441/97/1012/3
DiarrhoeaGastrointestinal disorders53/10319/446/934/1012/3
Dry skinSkin and subcutaneous tissue disorders21/1036/444/922/1012/3
DysgeusiaNervous system disorders32/1039/446/931/1011/3
HyperphosphataemiaMetabolism and nutrition disorders35/10313/444/956/1012/3
StomatitisGastrointestinal disorders48/10313/443/945/1011/3
ConstipationGastrointestinal disorders36/10311/444/933/1011/3
Decreased appetiteMetabolism and nutrition disorders32/10311/444/929/1010/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort A-ID: FGFR3 Mutations or FusionsCohort B-ID: All Other FGF/FGFR AlterationsOther-IDCohort A-CD: FGFR3 Mutations or FusionsOther-CDTotal
Mean67.6 ± 9.0965.1 ± 10.8369.3 ± 7.9868.5 ± 9.3960.3 ± 9.0267.5 ± 9.53
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A-ID: FGFR3 Mutations or FusionsCohort B-ID: All Other FGF/FGFR AlterationsOther-IDCohort A-CD: FGFR3 Mutations or FusionsOther-CDTotal
Female2914123168
Male74308782192
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A-ID: FGFR3 Mutations or FusionsCohort B-ID: All Other FGF/FGFR AlterationsOther-IDCohort A-CD: FGFR3 Mutations or FusionsOther-CDTotal
White64296632164
Black or African-American001001
Asian22012117
Turkish100001
Persian001001
Unknown or Not Reported3013122066
Missing6004010
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A-ID: FGFR3 Mutations or FusionsCohort B-ID: All Other FGF/FGFR AlterationsOther-IDCohort A-CD: FGFR3 Mutations or FusionsOther-CDTotal
Hispanic or Latino100203
Not Hispanic or Latino64327662171
Not Reported2311222159
Unknown510309
Captured as Other5006011
Missing500207
08

Study locations

96 sites
  • Arizona Oncology Associates (Wilmot)
    Tucson, Arizona 85711, United States
  • Sharp Memorial Hospital
    San Diego, California 92123, United States
  • UCSF Helen Diller Family Comprehensive Care Center
    San Francisco, California 94158, United States
  • Rocky Mountain Cancer Centers
    Boulder, Colorado 80303, United States
  • Calaway-Young Cancer Center at Valley View Hospital
    Glenwood Springs, Colorado 81601, United States
  • Mount Sinai Medical Center
    Miami Beach, Florida 33140, United States
  • Florida Hospital Cancer Institute
    Orlando, Florida 32804, United States
  • Emory University School of Medicine
    Atlanta, Georgia 30322, United States
  • University of Maryland, Greenebaum Cancer Center
    Baltimore, Maryland 21201, United States
  • Lahey Clinic Inc. - PARENT ACCOUNT
    Burlington, Massachusetts 01805, United States
  • Minnesota Oncology Hematology, P.A.
    Woodbury, Minnesota 55125, United States
  • GU Research Network
    Omaha, Nebraska 68130, United States
  • TRIO - Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169-3321, United States
  • New York Oncology Hematology, P.C.
    Albany, New York 12208, United States
  • Northwell Cancer Institute
    New Hyde Park, New York 11042, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45242, United States
  • Oregon Health & Science University
    Portland, Oregon 97229, United States
  • Compass Oncology the Northwest Cancer Specialists
    Tualatin, Oregon 97062, United States
  • St. Luke's Hospital
    Bethlehem, Pennsylvania 18015, United States
  • VA Pittsburgh Healthcare System
    Pittsburgh, Pennsylvania 15240, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Texas Oncology, P.A. - Austin
    Austin, Texas 78731, United States
  • Texas Oncology - Baylor Charles A. Sammons
    Dallas, Texas 75246, United States
  • Texas Oncology
    Houston, Texas 77024, United States
  • Texas Oncology, P.A. - Sherman
    Sherman, Texas 75090, United States
  • Baylor Scott & White Health
    Temple, Texas 76508, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Virginia Oncology Associates - Hampton
    Norfolk, Virginia 23502, United States
  • Northwest Medical Specialties, PLLC
    Tacoma, Washington 98405, United States
  • University of Wisconsic Hospital and Clinic
    Madison, Wisconsin 53792, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • UZ Antwerpen
    Edegem, 2650, Belgium
  • AZ Sint-Lucas - Campus Sint-Lucas
    Ghent, 9000, Belgium
  • AZ Groeninge Campus Loofstraat
    Kortrijk, 8500, Belgium
  • AZ Delta
    Roeselare, 8800, Belgium
  • Rigshospitalet
    Copenhagen, 2100, Denmark
  • CHU Besançon - Hôpital Jean Minjoz
    Besançon, Doubs 25030, France
  • Groupe Hospitalier Saint André - Hôpital Saint André
    Bordeaux, Gironde 33075, France
  • Institut Claudius Regaud-Oncopole
    Toulouse, Haute Garonne 31059, France
  • ICO - Site René Gauducheau
    Saint-Herblain, Loire Atlantique 44805, France
  • ICO - Site Paul Papin
    Angers, Maine Et Loire 49933, France
  • Hopital Saint Louis
    Paris, Paris 75010, France
  • Centre Leon Berard
    Lyon, Rhone 69373, France
  • CHU Strasbourg - Nouvel Hôpital Civil
    Strasbourg, Rhone 67091, France
  • Groupe Hospitalier Pitie-Salpetriere
    Paris, 75571, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin
    Berlin, 12200, Germany
  • Universitaetsklinikum Koeln
    Cologne, 50937, Germany
  • Klinikum Dresden Standort Dresden-Friedrichstadt
    Dresden, 01067, Germany
  • Universitaetsklinikum Carl Gustav Carus TU Dresden
    Dresden, 01307, Germany
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
    Mainz, 55131, Germany
  • Universitaetsklinikum Muenster
    Münster, 48149, Germany
  • Studienpraxis Urologie Drs. Feyerabend
    Nürtingen, 72622, Germany
  • Universitaetsklinikum Tuebingen
    Tübingen, 72076, Germany
  • Soroka University Medical Center
    Beersheba, 8410101, Israel
  • Assaf Harofeh Medical Center
    Be’er Ya‘aqov, 70300, Israel
  • Meir Medical Center
    Kfar Saba, 4428126, Israel
  • Chaim Sheba Medical Center
    Ramat Gan, 52656, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
    Bologna, 40138, Italy
  • Fondazione Del Piemonte Per L'Oncologia IRCC Candiolo
    Candiolo, 20133, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, 20133, Italy
  • Azienda Ospedaliera Di Rilievo Nazionale A. Cardarellio
    Naples, 80131, Italy
  • Ospedale degli Infermi
    Rimini, 47923, Italy
  • University Campus Bio-Medico di Roma
    Rome, 00128, Italy
  • IRCCS Ospedale Casa Sollievo della Sofferenza
    San Giovanni Rotondo, 71013, Italy
  • A.O.U. Senese Policlinico Santa Maria alle Scotte
    Siena, 53100, Italy
  • San Camillo-Forlanini Hospital
    Siena, 53100, Italy
  • Kyushu University Hospital
    Fukuoka, 8128582, Japan
  • Saitama Medical University International Medical Center
    Hidaka-shi, 350-1298, Japan
  • Hirosaki University Hospital
    Hirosaki-shi, 036-8563, Japan
  • Teikyo University Hospital
    Itabashi-ku, 173-8606, Japan
  • Nihon University Itabashi Hospital
    Itabashi-ku, 173-8610, Japan
  • Nara Medical University Hospital
    Kashihara-shi, 634-8522, Japan
  • Osaka International Cancer Institute
    Osaka, 541-8567, Japan
  • Saitama Cancer Center
    Saitama, 362-0806, Japan
  • Osaka University Hospital
    Suita-shi, 565-0871, Japan
  • Jichi Medical University Hospital
    Tochigi, 329-0498, Japan
  • VU Medisch Centrum
    Amsterdam, 1081 HV, Netherlands
  • Zorgsaam Ziekenhuis
    Terneuzen, 4535 PA, Netherlands
  • HagaZiekenhuis Van Den Haag
    The Hague, Netherlands
  • Viecuri Medisch Centrum
    Venlo, 5912 BL, Netherlands
  • Clinica Universidad de Navarra
    Pamplona, Navarre 31008, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • ICO Girona - Hospital Universitari de Girona Dr. Josep Trueta
    Girona, 17007, Spain
  • Centro Integral Oncologico Clara Campal
    Madrid, 28050, Spain
  • University College London Hospitals
    London, Greater London NW1 2PG, United Kingdom
  • Guy's Hospital
    London, Greater London SE1 9RT, United Kingdom
  • Charing Cross Hospital
    London, Greater London W6 8RF, United Kingdom
  • Nottingham University Hospitals City Campus
    Nottingham, Nottinghamshire NG5 1PB, United Kingdom
  • Beatson West of Scotland Cancer Centre
    Glasgow, Strathclyde G12 OYN, United Kingdom
  • Queen Elizabeth Hospital
    Birmingham, West Midlands B15 2TH, United Kingdom
09

References and documents

Publications

  • Zhang C, Huang MN, Shan JQ, Hu ZJ, Li ZW, Liu JY. Pemigatinib, a selective FGFR inhibitor overcomes ABCB1-mediated multidrug resistance in cancer cells. Biochem Biophys Res Commun. 2024 Jan 8;691:149314. doi: 10.1016/j.bbrc.2023.149314. Epub 2023 Nov 24. PubMed 38039831 ↗
  • Necchi A, Pouessel D, Leibowitz R, Gupta S, Flechon A, Garcia-Donas J, Bilen MA, Debruyne PR, Milowsky MI, Friedlander T, Maio M, Gilmartin A, Li X, Veronese ML, Loriot Y. Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201. Ann Oncol. 2024 Feb;35(2):200-210. doi: 10.1016/j.annonc.2023.10.794. Epub 2023 Nov 11. PubMed 37956738 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Feb 2022, 60 months.

Results were first posted in Mar 2023, 1 year 1 month after primary completion.

Of 119 phase 2 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 102. This study's 60 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2016
First posted
Aug 19, 2016
StartActual
Jan 12, 2017
Primary completionActual
Feb 1, 2022
CompletionActual
Feb 1, 2022
Results first posted
Mar 24, 2023
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02872714
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Aug 19, 2016
Start date
Jan 12, 2017
Primary completion
Feb 1, 2022
Completion
Feb 1, 2022
Results posted
Mar 24, 2023
Last update
Aug 14, 2025

Study contacts

Ekaterine Asatiani, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemigatinib

Start the discussion